We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Alun
Davies
+44 (0)208 3311 7320
a.h.davies@imperial.ac.uk
Dr
Sarah
Whittley
+44 (0)203 311 7371
s.whittley@imperial.ac.uk
Dr
Alun
Davies
+44 (0)208 3311 7320
a.h.davies@imperial.ac.uk
VTE prevention (in patients undergoing endovenous varicose vein interventions)
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg, known as deep veins. Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other problems. If a clot in the leg travels to the lungs, it may be life-threatening. Medicines to reduce the blood's tendency to form clots are often prescribed to patients at high risk of blood clots. However, it is unclear if these clot-reducing medicines are beneficial in preventing blood clots in people having these varicose vein procedures. Elastic stockings that squeeze the leg and improve the blood flow through the veins are applied after the varicose vein procedure which helps to reduce the risk of blood clots. This study will investigate if it is worthwhile to prescribe medicines to reduce blood clots after varicose vein procedures. People enrolled in the study will undergo an assessment to make sure that they don’t have the most important risk factors for clots.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38367965/ (added 19/02/2024)
You can take part if:
You may not be able to take part if:
Current exclusion criteria as of 06/03/2025:
1. Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation 2. Previous personal or first-degree relative history of VTE 3. Thrombophilia 4. Female patients of childbearing potential who have a positive pregnancy test 5. A history of allergy to heparins or direct oral anticoagulants 6. A history of heparin-induced thrombocytopenia 7. Inherited and acquired bleeding disorders 8. Evidence of active bleeding 9. Concomitant major health problems such as active cancer and chronic renal and/or liver impairment 10. Known thrombocytopenia (platelets known to be less than 50 x 10^9/l) 11. Major trauma or non-venous surgery that required local risk assessment for VTE in the previous 90 days12. Recent ischemic stroke in the previous 90 days 13. Inability to provide consent
_____
Previous exclusion criteria as of 12/01/2024:
1. Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation 2. Previous personal or first-degree relative history of VTE 3. Thrombophilia 4. Female patients of childbearing potential who have a positive pregnancy test 5. A history of allergy to heparins or direct oral anticoagulants 6. A history of heparin-induced thrombocytopenia 7. Inherited and acquired bleeding disorders 8. Evidence of active bleeding 9. Concomitant major health problems such as active cancer and chronic renal and/or liver impairment 10. Known thrombocytopenia (platelets known to be less than 50 x 10^9/l) 11. Surgery or major trauma in the previous 90 days 12. Recent ischemic stroke in the previous 90 days 13. Inability to provide consent
_____
Previous exclusion criteria:
1. Clinical indication for therapeutic anticoagulation 2. Clinical contraindication to anticoagulation3. Previous personal or family history of VTE4. Thrombophilia 5. Inability to provide informed consent or consent by personal/professional legal representative6. A positive test for SARS-CoV2 <3 months of procedure7. Female patients of childbearing age who have a positive pregnancy test
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Sarah
Whittley
+44 (0)203 311 7371
s.whittley@imperial.ac.uk
Prof
Alun
Davies
+44 (0)208 3311 7320
a.h.davies@imperial.ac.uk
Dr
Alun
Davies
+44 (0)208 3311 7320
a.h.davies@imperial.ac.uk
The study is sponsored by Imperial College London and funded by Health Technology Assessment Programme.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 55506
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
